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abstract
 
The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated
epithelial Cl
 

 
 channel that, when defective, causes cystic fibrosis. Screening of a collection of 100,000 diverse
small molecules revealed four novel chemical classes of CFTR inhibitors with K
 
i
 
 
 

 
 10 
 

 
M, one of which (glycine
hydrazides) had many active structural analogues. Analysis of a series of synthesized glycine hydrazide analogues
revealed maximal inhibitory potency for 
 
N
 
-(2-naphthalenyl) and 3,5-dibromo-2,4-dihydroxyphenyl substituents.
The compound 
 
N
 
-(2-naphthalenyl)-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene]glycine hydrazide (GlyH-101)
reversibly inhibited CFTR Cl
 

 
 conductance in 
 

 
1 min. Whole-cell current measurements revealed voltage-depen-
dent CFTR block by GlyH-101 with strong inward rectification, producing an increase in apparent inhibitory
constant K
 
i
 
 from 1.4 
 

 
M at 
 

 
60 mV to 5.6 
 

 
M at 
 

 
60 mV. Apparent potency was reduced by lowering extracellular
Cl
 

 
 concentration. Patch-clamp experiments indicated fast channel closures within bursts of channel openings,
reducing mean channel open time from 264 to 13 ms (
 

 
60 mV holding potential, 5 
 

 
M GlyH-101). GlyH-101
inhibitory potency was independent of pH from 6.5–8.0, where it exists predominantly as a monovalent anion
with solubility 
 

 
1 mM in water. Topical GlyH-101 (10 
 

 
M) in mice rapidly and reversibly inhibited forskolin-
induced hyperpolarization in nasal potential differences. In a closed-loop model of cholera, intraluminal
GlyH-101 (2.5 
 

 
g) reduced by 
 

 
80% cholera toxin–induced intestinal fluid secretion. Compared with the thiazo-
lidinone CFTR inhibitor CFTR
 
inh
 
-172, GlyH-101 has substantially greater water solubility and rapidity of action,
and a novel inhibition mechanism involving occlusion near the external pore entrance. Glycine hydrazides may
be useful as probes of CFTR pore structure, in creating animal models of CF, and as antidiarrheals in enterotoxic-
mediated secretory diarrheas.
 
key words:
 
cystic fibrosis • diarrhea • high-throughput screening • patch-clamp • drug discovery
 
I N T R O D U C T I O N
 
The cystic fibrosis transmembrane conductance regula-
tor (CFTR) protein is a cAMP-activated Cl
 

 
 channel
expressed in secretory and absorptive epithelia in the
airways, pancreas, intestine, testis, and other tissues
(Pilewski and Frizzell, 1999). Mutations in CFTR that
reduce or inhibit its function cause the genetic disease
cystic fibrosis (CF), which is characterized by chronic lung
infection and pancreatic insufficiency, with progressive
deterioration in lung function and death. There is
considerable interest in the development and charac-
terization of CFTR inhibitors as probes of the CFTR
Cl
 

 
 transport mechanism, and as reagents to reduce
CFTR function in vivo for creation of animal models of
CF and as clinical antidiarrheals in CFTR-dependent
secretory diarrheas caused by 
 
Vibrio cholera
 
 and 
 
Escherichia
coli
 
 (Thiagarajah and Verkman, 2003). CFTR inhibitors
also have potential applications in polycystic kidney
disease, as male contraceptives, and in reducing airway
glandular secretions in infectious and allergic bronchitis/
rhinitis (Gong et al., 2001; Nakanishi et al., 2001;
Thiagarajah et al., 2004b).
Several CFTR inhibitors have been introduced,
though most having weak potency and lacking CFTR
specificity. The oral hypoglycemic agent glibenclamide
inhibits CFTR Cl
 

 
 conductance from the intracellular
side by an open channel blocking mechanism (Sheppard
and Robinson, 1997; Zhou et al., 2002) at high micro-
molar concentrations where it affects other Cl
 

 
 and
cation channels (Sturgess et al., 1988; Rabe et al., 1995;
Schultz et al., 1999). Other nonselective anion trans-
port inhibitors, including diphenylamine-2-carboxyl-
ate (DPC), 5-nitro-2(3-phenylpropyl-amino)benzoate
(NPPB), and flufenamic acid, also inhibit CFTR at high
 
Address correspondence to Alan S. Verkman, 1246 Health Sciences
East Tower, Cardiovascular Research Institute, University of California,
San Francisco, San Francisco, CA 94143-0521. Fax: (415) 665-3847;
email: verkman@itsa.ucsf.edu
 
Abbreviations used in this paper:
 
 AceH, acetic acid hydrazide; CFTR,
cystic fibrosis transmembrane conductance regulator; FRT, Fisher rat
thyroid; GlyH, glycine hydrazide; OxaH, oxamic hydrazide.
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concentrations by occluding the pore at an intracellu-
lar site (Dawson et al., 1999; McCarty, 2000).
Our laboratory developed a high-throughput screen-
ing assay for discovery of CFTR activators and inhibi-
tors (Galietta et al., 2001). CFTR halide transport func-
tion is quantified from the time course of fluorescence
in response to an iodide gradient in cells coexpressing
a green fluorescent protein–based halide sensor (Ja-
yaraman et al., 2000; Galietta et al., 2001) and wild-type
CFTR or a CF-causing CFTR mutant. The assay was
used to identify small-molecule activators of wild type
and 
 

 
F508-CFTR with activating potencies down to 100
nM (Ma et al., 2002b; Yang et al., 2003). A thiazolidi-
none class of CFTR inhibitors was identified by screen-
ing of a collection of 50,000 small, drug-like molecules
(Ma et al., 2002a). The lead compound CFTR
 
inh
 
-172 in-
hibited CFTR Cl
 

 
 conductance in a voltage-indepen-
dent manner, probably by binding to the NBD1 do-
main at the cytoplasmic surface of CFTR (Ma et al.,
2002a; Taddei et al., 2004). In intact cells, CFTR Cl
 

 
channel function was 50% inhibited at CFTR
 
inh
 
-172
concentrations of 0.3–3 
 

 
M depending on cell type
and membrane potential. CFTR
 
inh
 
-172 inhibited intesti-
nal fluid secretion in response to cholera toxin and
heat-stable (STa) 
 
E. coli
 
 toxin in rodents (Thiagarajah
et al., 2004a), and resulted in the secretion of viscous,
CF-like fluid from submucosal glands in pig and hu-
man trachea (Thiagarajah et al., 2004b).
Although thiazolidinones are potentially useful as an-
tidiarrheals and for the creation of CF animal models,
they have limited water solubility (
 

 
20 
 

 
M) and inhibit
CFTR by binding to its cytoplasmic-facing surface, re-
quiring cell penetration with consequent systemic ab-
sorption when administered orally. The purpose of this
work was to identify CFTR inhibitors with high water
solubility that occlude the CFTR pore by binding to a
site at its external surface. A low stringency, high-
throughput screen of 100,000 small molecules was per-
formed to identify novel chemical scaffolds with CFTR
inhibitory activity. We identified several new classes of
CFTR inhibitors, one of which was highly water soluble,
blocked CFTR by occlusion of the CFTR pore near its
external surface, and inhibited CFTR function in vivo
in rodent models.
 
M A T E R I A L S  A N D  M E T H O D S
 
High-throughput Screening for Identification of CFTR Inhibitors
 
Screening was performed using an integrated system (Beckman
Coulter) consisting of a 3-m robotic arm, CO
 
2
 
 incubator, plate
washer, liquid handling work station, barcode reader, delidding
station, plate sealer, and two fluorescence plate readers (Op-
tima; BMG Lab Technologies), each equipped with two syringe
pumps and HQ500/20X (500 
 

 
 10 nm) excitation and HQ535/
30M (535 
 

 
 15 nm) emission filters (Chroma Technology
Corp.). 100,000 small molecules (most 250–550 D) were se-
lected for screening from commercial sources (ChemBridge
and ChemDiv) using algorithms designed to maximize chemical
diversity and drug-like properties. Compounds were stored fro-
zen as 2.5 mM stock solutions in DMSO. Fisher rat thyroid
(FRT) cells stably expressing wild-type human CFTR and YFP-
H148Q were cultured on 96-well black-wall plates as described
previously (Ma et al., 2002b). For screening, cells in 96-well
plates were washed three times, and then CFTR halide conduc-
tance was activated by incubation for 15 min with an activating
cocktail containing 10 
 

 
M forskolin, 20 
 

 
M apigenin, and 100
 

 
M IBMX. Test compounds (25 
 

 
M final) were added 5 min be-
fore assay of iodide influx in which cells were exposed to a 100
mM inwardly directed iodide gradient. YFP fluorescence was re-
corded for 2 s before and 12 s after creation of the iodide gradi-
ent. Initial rates of iodide influx were computed from the time
course of decreasing fluorescence after the iodide gradient
(Yang et al., 2003).
 
Apical Cl
 

 
 Current and Short-circuit Current Measurements
 
FRT, T84, and human airway epithelial cells were cultured on
Snapwell filters with 1 cm
 
2
 
 surface area (Corning-Costar) to re-
sistances 
 

 
1,000 
 

 
·cm
 
2
 
 as described previously (Ma et al.,
2002b). Filters were mounted in an Easymount Chamber System
(Physiologic Instruments). For apical Cl
 

 
 current measurements
on FRT cells, the basolateral hemichamber was filled with buffer
containing (in mM) 130 NaCl, 2.7 KCl, 1.5 KH
 
2
 
PO
 
4
 
, 1 CaCl
 
2
 
, 0.5
MgCl
 
2
 
, 10 Na-HEPES, 10 glucose (pH 7.3). The basolateral
membrane was permeabilized with amphotericin B (250 
 

 
g/ml)
for 30 min before measurements. In the apical solution, 65 mM
NaCl was replaced by sodium gluconate, and CaCl
 
2
 
 was in-
creased to 2 mM. For short-circuit current measurements in
(nonpermeabilized) T84 and human airway cells, both hemi-
chambers contained Kreb’s solution (in mM): 120 NaCl, 25
NaHCO
 
3
 
, 3.3 KH
 
2
 
PO
 
4
 
, 0.8 K
 
2
 
HPO
 
4
 
, 1.2 MgCl
 
2
 
, 1.2 CaCl
 
2
 
, and 10
glucose (pH 7.3). Solutions were bubbled with 95% O
 
2
 
/5% CO
 
2
 
and maintained at 37
 
	
 
C. For studies in mouse intestine, ileal seg-
ments were isolated, washed with ice-cold Kreb’s buffer, opened
longitudinally through the mesenteric border, and mounted in
a micro-Ussing chamber (0.7 cm
 
2
 
 aperture area; World Precision
Instruments). Hemichambers were filled with Kreb’s solutions
containing 10 
 

 
M indomethacin. Apical Cl
 

 
/short-circuit cur-
rent was recorded using a DVC-1000 voltage-clamp (World Pre-
cision Instruments) with Ag/AgCl electrodes and 1 M KCl agar
bridges.
 
Patch-clamp Analysis
 
Patch-clamp experiments were performed at room temperature
on FRT cells stably expressing wild-type CFTR. Cell-attached and
whole-cell configurations were used (Hamill et al., 1981). The
cell membrane was clamped at specified voltages using an EPC-7
patch-clamp amplifier (List Medical). Data were filtered at 500
Hz and digitized at 2000 Hz. For whole-cell experiments, the pi-
pette solution contained (in mM): 120 CsCl, 10 TEA-Cl, 0.5
EGTA, 1 MgCl
 
2
 
, 40 mannitol, 10 Cs-HEPES, and 3 mM MgATP
(pH 7.3). For cell-attached experiments, EGTA was replaced with
1 mM CaCl
 
2
 
. The bath solution for whole-cell experiments con-
tained (in mM): 150 NaCl, 1 CaCl
 
2
 
, 1 MgCl
 
2
 
, 10 glucose, 10 man-
nitol, 10 Na-TES (pH 7.4). In some experiments bath solution
NaCl was reduced to 20 mM (mannitol added to maintain osmo-
lality). In cell-attached experiments, the bath solution contained
(in mM): 130 KCl, 2 NaCl, 2 CaCl
 
2
 
, 2 MgCl
 
2
 
, 10 glucose, 20 man-
nitol, and 10 K-Hepes (pH 7.3). Inhibitors were applied by extra-
cellular perfusion. CFTR Cl
 

 
 channel activity in cell-attached
patches was analyzed as described previously (Taddei et al.,
2004). The number of CFTR channels present in each patch was
estimated as the maximum number of simultaneous channel
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openings detected in the presence of 5 
 

 
M forskolin in a contin-
uous recording of at least three minutes.
 
Nasal Potential Difference Measurements in Mice
 
After anesthesia with intraperitoneal ketamine (90–120 mg/kg)
and xylazine (5–10 mg/kg), the airway was protected by orotra-
cheal intubation with a 21-gauge angiocatheter as previously de-
scribed (Salinas et al., 2004). A PE-10 cannula pulled to a tip di-
ameter of 0.3 mm was inserted into one nostril 5 mm distal to
the anterior nares and connected though a 1 M KCl agar bridge
to a Ag/AgCl electrode and high-impedance digital voltmeter
(IsoMillivolt Meter; World Precision Instruments). The nasal can-
nula was perfused at 50 
 

 
L/min using dual microperfusion
pumps serially with PBS, low chloride PBS (chloride lowered to
4.7 mM by substitution with gluconate), low chloride PBS con-
taining forskolin (10 
 

 
M) without and then with GlyH-101 (10
 

 
M), and then PBS. In some studies GlyH-101 (10 
 

 
M) or DIDS
(100 
 

 
M) was present in all solutions. The reference electrode
was a PBS-filled 21-gauge needle inserted in the subcutaneous tis-
sue in the abdomen and connected to a second Ag/AgCl elec-
trode by a 1 M KCl agar bridge.
 
Intestinal Fluid Secretion Measurements
 
Mice (CD1 strain, 25–35 g) were deprived of food for 24 h and
anaesthetized with intraperitoneal ketamine (40 mg/kg) and xy-
lazine (8 mg/kg). Body temperature was maintained at 36–38
 
	
 
C
using a heating pad. Following a small abdominal incision three
closed ileal loops (length 20–30 mm) proximal to the cecum
were isolated by sutures. Loops were injected with 100 
 

 
l of PBS
or PBS containing cholera toxin (1 
 

 
g) without or with GlyH-101
(2.5 
 

 
g). The abdominal incision was closed with suture and
mice were allowed to recover from anesthesia. At 4 h the mice
were anaesthetized, intestinal loops were removed, and loop
length and weight were measured to quantify net fluid secretion.
Mice were killed by an overdose of ketamine and xylazine. All
protocols were approved by the UCSF Committee on Animal
Research.
 
Synthesis Procedures
 
Procedures were developed for synthesis of glycine hydrazide an-
alogues (see Table I and Fig. 3 B). All synthesized compounds
had 
 

 
98% purity (TLC/HPLC) and were confirmed by mass and
 
1
 
H nmr spectrometry (typical data for GlyH-101 given below).
 
N-2-naphthalenyl-[(3,5-dibromo-2,4-dihydroxyphenyl) 
methylene] Glycine Hydrazide (GlyH-101) and Related 
Glycine Hydrazides (GlyH-102–109, 114–127) and Acetic 
Acid Hydrazides (AceH-401–404)
 
A mixture of 2-naphthylamine (compound I, see Fig. 3 B) (1.43 g,
10 mmol), ethyl iodoacetate (2.14 g, 10 mmol), and sodium ac-
etate (1.64 g, 20 mmol, dissolved in 2 ml of water) was stirred
at 90
 
	
 
C for 3 h. The solid material obtained upon cooling was fil-
tered and recrystallized from hexane to yield 1.5 g ethyl 
 
N
 
-(2-
naphthalenyl)glycinate (II, yield, 65%, mp 83–84
 
	
 
C) (Ramamur-
thy and Bhatt, 1989). A solution of above product (2.29 g, 10
mmol) in ethanol (10 ml) was refluxed with hydrazine hydrate
(0.6 g, 12 mmol) for 10 h. Solvent and excess reagent were dis-
tilled under vacuum. The product was recrystallized from etha-
nol to yield 1.8 g of 
 
N
 
-(2-naphthalenyl)glycine hydrazide (com-
pound III) (82%, mp 147–148
 
	
 
C). A mixture of compound III
(2.15 g, 10 mmol) and 3,5-dibromo-2,4-dihydroxybenzaldehyde
(3 g, 10 mmol) in ethanol (5 ml) was refluxed for 3 h. The hydra-
zone that crystallized upon cooling was filtered, washed with eth-
anol, and recrystallized from ethanol to give 3.8 g (78%) of
GlyH-101. Melting point (mp) 
 

 
300
 
	
 
C, ms (ES
 

 
): M/Z 492
(M-H)
 

 
1
 
; 
 
1
 
H nmr (DMSO-d
 
6
 
): 
 


 
 4.1(s, 2H, CH
 
2
 
), 6.5–7.5 (m, 9H,
aromatic, NH), 8.5 (s, 1H, CH
 

 
N), 10.4 (s, 1H, NH-CO), 11.9 (s,
1H, OH), 12.7(s, 1H, OH). Compounds GlyH-102–109, GlyH-
114–127, and AceH-401–404 were synthesized similarly by con-
densing appropriate hydrazides with substituted benzaldehydes
or acetophenones.
 
N-(6-quinolinyl)-[(3,5-dibromo-2,4-dihydroxyphenyl) 
methylene] Glycine Hydrazide (GlyH-126) and Related 
Quinolinyl-Glycine Hydrazides
 
To a stirred solution of 6-aminoquinoline (compound IV) (0.72 g,
5 mmol) in acetonitrile (20 ml) was added 33% aqueous glyox-
ylic acid (1.85 g, 20 mmol) solution. A solution of NaBH
 
3
 
CN
(0.64 g, 10.2 mmol) in acetonitrile (20 ml) was then added at 3
 
	
 
C
over 20 min and the reaction mixture was warmed to room tem-
perature and stirred for 48 h. Acetonitrile was evaporated under
vacuum, water (20 ml) was added to the residue, the solution was
alkalinized to pH 9.5, and unreacted amine was extracted with
ether. Concentrated HCl (25 ml) was added to the aqueous solu-
tion and the mixture was stirred at 25
 
	
 
C for 1 h. Solvent was evap-
orated under vacuum. The resultant residue of 
 
N
 
-(6-quinoli-
nyl)glycine was dissolved in dry ethanol (50 ml) saturated with
dry HCl, stirred overnight and then refluxed for 3 h. Ethanol was
evaporated, the ester hydrochloride was suspended in dry ether,
and ammonia gas was bubbled. The ammonium chloride was fil-
tered and ether was removed by evaporation to give ethyl 
 
N-
 
(6-
quinolinyl)glycinate (0.5 g, 87%, mp 122–123
 
	
 
C, Ramamurthy
and Bhatt, 1989). 
 
N-
 
(6-quinolinyl)glycine hydrazide (compound
VI), synthesized by hydrazinolysis of the above ester, was reacted
with 3,5-dibromo-2,4-dihydroxybenzaldehyde to give GlyH-126.
Similar procedures were used for synthesis of GlyH-127.
Oxamic Hydrazides (OxaH-110–113)
The oxamic hydrazides were synthesized by heating a mixture of
2-naphthaleneamine with diethyl oxalate in toluene. The result-
ant N-substituted oxamic acid ethyl ester was treated with hydra-
zine hydrate followed by condensation with substituted benzalde-
hydes or acetophenones to yield compounds OxaH-110–113.
3,5-Dibromo-4-hydroxy-[2-(2-naphthalenamine)aceto] Benzoic 
Acid Hydrazide (GlyH-202) and Related GlyH-201 and 
Oxa-203–204
N-(2-naphthalenyl)glycine hydrazide (compound III, 2.15 g, 10
mmol) was reacted with 3,5-dibromo-4-hydroxybenzoyl chloride
(3.14 g, 10 mmol) (Gilbert et al., 1982) in pyridine (10 ml) for 5 h.
Pyridine was removed and the residue was diluted with water.
The product was recrystallized from ethanol to yield a gray pow-
der 3.8 g (77%), mp  300	C. Compounds GlyH-201 and Oxa-
203–204 were synthesized by similar procedure.
N-2-naphthalenyl-[(3,5-dibromo-2,4-dihydroxyphenyl)methyl] 
Glycine Hydrazide (GlyH-301) and Related Glycine Hydrazides 
(GlyH-302, OxaH-303–304)
A mixture of GlyH-101 (1.5 g, 3 mmol), hydrazine hydrate (0.15
ml, 3 mmol), and Pd/C catalyst (0.1 g, 10% Pd) in 5 ml of di-
methylformamide was refluxed for 6–8 h (Verma et al., 1984).
The reaction mixture was filtered, diluted with cold water, and
extracted with diethyl ether. GlyH-301 was crystallized from ether
to yield 0.9 g (60%), mp 258–260	C. Compounds GlyH-302 and
OxaH-303–304 were prepared similarly.
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R E S U L T S
Discovery of Novel Classes of CFTR Inhibitors
A collection of 100,000 small, drug-like compounds
with high chemical diversity was screened to identify
new CFTR inhibitors. As diagrammed in Fig. 1 A, com-
pounds were screened at 25 M in a cell-based assay of
iodide influx after CFTR activation by an agonist mix-
ture containing a cAMP agonist (forskolin, 10 M),
phosphodiesterase inhibitor (IBMX, 100 M), and fla-
vone-type direct CFTR activator (apigenin, 20 M). Ini-
tial rates of iodide influx were computed from the ki-
netics of fluorescence decrease after chloride replace-
ment by iodide. Four compounds (Fig. 1 B) reducing
iodide influx by 50% were identified, none of which
are related structurally to known CFTR activators or in-
hibitors. 12 compounds reduced iodide influx by 25–
50%, most of which were related structurally to the
compounds in Fig. 1 B or to the thiazolidinones.
To select inhibitor(s) for further evaluation, dose–
response measurements were done for the compounds
in Fig. 1 B, and CFTR inhibition was confirmed electro-
physiologically by measuring apical Cl current. Ki was
7, 5, 5, and 5 M for compounds a–d, respectively.
Fig. 1 C shows representative fluorescence (left) and
apical Cl current (right) data for compound d. We
next screened 100–250 commercially available ana-
logues of each compound class to determine whether
active structural analogues exist, an important prereq-
uisite for follow-up compound optimization by synthe-
sis of targeted analogues. Whereas few or no active ana-
logues of compounds a, b and c were found, initial
screening of 285 analogues of compound d (substi-
tuted glycine hydrazides, GlyH) revealed 34 analogues
that inhibited CFTR-mediated iodide influx by 25%
at 25 M.
Prior to extensive structure–activity analysis of synthe-
sized GlyH analogues and characterization of inhibition
mechanism, we determined the time course of GlyH-101
action and reversibility, and whether inhibition was effec-
tive for different CFTR-activating mechanisms. Fig. 2 A
shows prompt inhibition of iodide influx in the fluores-
cence and apical Cl current (inset) assays upon GlyH-
101 addition. Interestingly 50% of the inhibition oc-
curred within the 1-s addition/mixing time, with fur-
ther inhibition over 1 min. Fig. 2 B indicates complete
reversal of inhibition after GlyH-101 washout with 75%
reversal over 5 min. Fig. 2 C shows effective CFTR inhibi-
tion by GlyH-101 after activation by different types of ag-
onists, including potent direct activators of CFTR that do
not elevate cytosolic cAMP or inhibit phosphatase activ-
ity (CFTRact-02, 08, and 10; Ma et al., 2002b).
Figure 1. Identification of
novel classes of CFTR inhibi-
tors by high-throughput
screening. (A) Screening
procedure. FRT cells coex-
pressing a halide-sensing
yellow fluorescent protein
(YFP-H148Q) and human
wild-type CFTR were incu-
bated with activating cocktail
for 15 min before addition of
test compounds at 25 M.
Iodide influx was induced by
rapid addition of an iodide-
containing solution. (B)
Structures of novel classes of
CFTR inhibitors identified by
screening of a collection of
100,000 drug-like small mole-
cules. (C) Dose inhibition
of the glycine hydrazide
GlyH-101 determined by fluo-
rescence assay (left) and
apical Cl current analysis
(right). Apical Cl current
was induced by 100 M CPT-
cAMP. CPT-cAMP and GlyH-
101 were added to both apical
and basolateral solutions.
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GlyH-101 specificity was tested in an assay measuring
the activity of MDR-1, a drug transporter of the ATP
binding cassette family with structural homology to
CFTR. Cells overexpressing MDR-1 (9HTEo-/Dx) do
not incorporate rhodamine 123 as a consequence of
MDR-1–mediated extrusion. GlyH-101 at 20 M did not
increase rhodamine 123 uptake, whereas the MDR-1
inhibitor verapamil at 100 M increased rhodamine
123 incorporation by greater than fivefold (not de-
picted). As measured by short-circuit current in T84
cells after simulation by 5 M thapsigargin (in the pres-
ence of 10 M CFTRinh-172 to block CFTR), GlyH-101
at 5 M did not inhibit calcium-induced Cl channel
activity, whereas inhibition of 50% was seen at 50 M
GlyH-101 (not depicted).
Chemistry and Structure–Activity Relationships of 
Glycine Hydrazides
The GlyH-101 structure was modified systematically to
establish structure–activity relationships and to iden-
tify analogues with improved CFTR inhibitory activity.
Fig. 3 A shows the various classes of structural ana-
logues that were synthesized and tested for CFTR inhi-
bition. Structural modifications were done on both
ends of the glycine hydrazide backbone (Fig. 3 A, left,
top, and middle). Replacing the glycine methylene
group by a carbonyl group and replacing nitrogen by
oxygen generated oxamic acid hydrazides (OxaH,
right, top) and acetic acid hydrazides (AceH, right,
middle), respectively. The hydrazone group modifica-
tion produced two important series of compounds
(middle, bottom and right, bottom). Also shown are
compounds containing an additional methyl group at
the hydrazone bond (top, middle), and containing a
6-quinolinyl group replacing the naphthalenyl group
(left, bottom).
Fig. 3 B shows the reaction schemes developed for
synthesis of the different classes of glycine hydrazide
analogues (see materials and methods). Synthesis of
GlyH-101 involves reaction of 2-naphthalenamine with
ethyl iodoacetate followed by reactions with hydrazine
hydrate and 2,4-dihydroxy-3,5-dibromobenzaldehyde.
A similar procedure was used for most of the remaining
glycine hydrazide derivatives (listed in Table I). The
heteroaromatic analogues containing a 6-quinolin-
ium group required different synthetic route in which
6-aminoquinoline was condensed with glyoxalic acid,
and reduced using sodium cyanoborohydride (yielding
N-[6-quinolinyl]glycine; Ramamurthy and Bhatt, 1989),
which was further esterified and reacted with hydrazine
hydrate and benzaldehyde. The oxamic acid hydrazides
were synthesized starting from aromatic amines and di-
ethyl oxalate.
Modifications were made initially on the N-aryl (R1)
and benzaldehyde (R3) positions (see Table I and Fig. 4
for definition of Ri and CFTR inhibition). Good CFTR
inhibition was found when R3 contained 3,5-dibromo
and at least one hydroxyl substituent at the 4-position
(GlyH-102, 105, 114); addition of a second hydroxyl
group increased inhibition (GlyH-101, 104, 115–116).
Inhibition was greatly reduced when R3 contained
4-bromophenyl or 4-carboxyphenyl substituents (GlyH-
120–121). In addition, the 4-hydroxyl group in GlyH-
101 was important for inhibition since its 4-methoxy an-
Figure 2. CFTR inhibition by the glycine hydrazide GlyH-101.
Studies were done in FRT cells coexpressing human wild-type
CFTR and a halide-sensing yellow fluorescent protein (YFP). (A)
Kinetics of CFTR inhibition. After CFTR stimulation by a mixture
of activators (10 M forskolin, 100 M IBMX, 20 M apigenin),
iodide influx (mean  SEM, n  3) was measured by the fluores-
cence assay at indicated times after addition of GlyH-101 (10 M).
Inset shows reduction in apical Cl current (activated by 100 M
CPT-cAMP) after rapid addition of GlyH-101 (5 M). (B) Kinetics
of reversal of inhibition after GlyH-101 washout. FRT cells were
incubated with the mixture of activators containing 5 M GlyH-
101 for 5 min. GlyH-101 was removed and cells were washed three
times with PBS. Iodide influx was measured at specified times after
GlyH-101 washout in the presence of the activator mixture. (C)
Inhibition of iodide influx (mean  SEM, filled bars) by GlyH-101
(50 M, open bars) after CFTR stimulation by indicated agonists
(all 50 M, except for forskolin 10 M, CPT-cAMP 500 M).
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alogue, GlyH-103, had little activity. Similar structure–
activity results were found for GlyH-115 and GlyH-122.
R1 group modifications were performed, maintaining
R3 as 2,4-dihydroxy-3,5-dibromophenyl and 3,5-dibromo-
4-hydroxyphenyl. Analogues with R1 as 2-naphthalenyl
were much better inhibitors than R1 as 4-chlorophenyl
or 4-methylphenyl. Replacement of the 2-naphthalenyl of
GlyH-101 by 1-naphthalenyl (GlyH-104) decreased in-
hibition activity substantially, supporting the require-
ment of the 2-naphthalenyl substituent. GlyH-124–125,
containing a 2-anthacenyl group, were weakly active.
Replacement of 2-naphthalenyl group in GlyH-101 and
GlyH-102 by more polar heteroaromatic rings, such as
6-quinolinyl, gave compound with little activity (Gly-
126–127), as did the 2-naphthoxy analogues AceH-401
and AceH-402.
R2 was next modified (replacing methylene), keeping
2-naphthalenyl as R1 and dibromo-dihydroxyphenyl as
R3. Introduction of a carbonyl group in GlyH-101 and
GlyH-102 at R2, giving OxaH-110 and OxaH-111, gave
two to threefold greater inhibitory potency. Replace-
ment of CH2 by CHCH3 (GlyH-106–107) had minimal
effect on CFTR inhibition. In another structural varia-
tion, addition of a methyl group at R4 to GlyH-102,
yielding GlyH-109, gave improved CFTR inhibition.
Modification of the NC group in GlyH-101 and GlyH-
Figure 3. Glycine hydrazide
(GlyH) CFTR inhibitors. (A) Classes
of GlyH-101 analogues prepared for
analysis of structure–activity relation-
ships showing sites of modification
(brackets). Substitutions to benzal-
dehyde phenyl rings not shown. (B)
Reaction schemes for the synthesis
of GlyH-101, 126, 201, and 301.
Reagents and conditions (see mate-
rials and methods for details): (a)
ICH2COOEt, NaOAc, 95	C; (b)
N2H4.H2O, EtOH/reflux; (c) 3,5-
di-Br-2,4-di-OH-Ph-CHO, EtOH/
reflux; (d) 3,5-di-Br-2,4-di-OH-Ph-
COCl, pyridine, 22	C; (e) N2H4.H2O,
Pd/C (10%), DMF/reflux; (f) glyox-
alic acid, 10	C; (g) Na2BH3CN/
CH3CN, 48 h; dry HCl, EtOH. (C)
Structure (left) and apical Cl
current analysis (right, done as in
Fig. 1 C) of OxaH-110 in FRT cells.
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T A B L E  I
Structure–Activity Relationships of Glycine Hydrazides (See Fig. 4 for Structures)
Group 1
Glycine hydrazides (GlyH, R2  CH2)
Oxamic acid hydrazides (OxaH, R2  CO)
Active compounds
Compound R1 R2 R3 R4 Ki (M) % inhibition at 50 M
GlyH-101 2-naphthalenyl CH2 3,5-di-Br-2,4-di-OH-Ph H 4.3 95
GlyH-102 2-naphthalenyl CH2 3,5-di-Br-4-OH-Ph H 4.7 98
GlyH-103 2-naphthalenyl CH2 3,5-di-Br-2-OH-4-OMe-Ph H 20 56
GlyH-104 1-naphthalenyl CH2 3,5-di-Br-2,4-di-OH-Ph H 12 86
GlyH-105 1-naphthalenyl CH2 3,5-di-Br-4-OH-Ph H 15 87
GlyH-106 2-naphthalenyl CHCH3 3,5-di-Br-2,4-di-OH-Ph H 6 91
GlyH-107 2-naphthalenyl CHCH3 3,5-di-Br-4-OH-Ph H 10 80
GlyH-108 2-naphthalenyl CH2 3,5-di-Br-2,4-di-OH-Ph CH3 10 81
GlyH-109 2-naphthalenyl CH2 3,5-di-Br-4-OH-Ph CH3 4.7 100
OxaH-110 2-naphthalenyl CO 3,5-di-Br-2,4-di-OH-Ph H 2.7 86
OxaH-111 2-naphthalenyl CO 3,5-di-Br-4-OH-Ph H 5 80
OxaH-112 2-naphthalenyl CO 3,5-di-Br-2,4-di-OH Ph CH3 3 95
OxaH-113 2-naphthalenyl CO 3,5-di-Br-4-OH-Ph CH3 3 90
GlyH-114 4-Cl-Ph CH2 3,5-di-Br-4-OH-Ph H 5 95
GlyH-115 4-Cl-Ph CH2 3,5-di-Br-2,4-di-OH Ph H 6.7 91
GlyH-116 4-Me-Ph CH2 3,5-di-Br-2,4-di-OH Ph H 10 79
Weakly active compounds (Ki  25–50 M)
Compound R1 R2 R3 R4
GlyH-117 2-Me-Ph CH2 3,5-di-Br-2,4-di-OH Ph H
GlyH-118 1-naphthalenyl CH2 3-Br-4-OH-Ph H
GlyH-119 2-naphthalenyl CH2 2,4-di-OH-Ph H
GlyH-120 2-naphthalenyl CH2 4-Br-Ph H
GlyH-121 2-naphthalenyl CH2 4-carboxy-Ph H
GlyH-122 4-Cl-Ph CH2 3,5-di-Br-2-OH-4-OMe-Ph H
GlyH-123 4-Cl-Ph CH2 2,4-di-OH-Ph H
GlyH-124 2-anthracenyl CH2 3,5-di-Br-2,4-di-OH Ph H
GlyH-125 2-anthracenyl CH2 3,5-di-Br-4-OH-Ph H
GlyH-126 6-quinolinyl CH2 3,5-di-Br-2,4-di-OH Ph H
GlyH-127 6-quinolinyl CH2 3,5-di-Br-4-OH-Ph H
Inactive compounds (Ki  50 M)
R1  Ph, Monosubstituted-Ph: Alkyl, halo, alkoxy
Disubstituted-Ph: Dihalo, hydroxyalkoxy
Trisubstituted-Ph: Trihalo, dihaloalkyl
R2  CH2 R3  Ph, Monosubstituted-Ph: alkyl, halo, alkoxy, aryloxy, aryl, nitro, hydroxy, 
dialkylamino
Disubstituted-Ph: dihalo, dihydroxy, dialkyl, haloalkyl, hydroxyalkoxy, dialkoxy
Trisubstituted-Ph: alkyl/alkoxyhalohydroxy
Group 2
Compound R1 R2 R3 Ki (M) % inhibition at 50 M
GlyH-201 2-naphthalenyl CH2 3,5-di-Br-2,4-di-OH Ph 20 65
GlyH-202 2-naphthalenyl CH2 3,5-di-Br-4-OH-Ph 22 57
OxaH-203 2-naphthalenyl CO 3,5-di-Br-2,4-di-OH Ph 50
OxaH-204 2-naphthalenyl CO 3,5-di-Br-4-OH-Ph 50
Group 3
Compound R1 R2 R3 Ki (M) % inhibition at 50 M
GlyH-301 2-naphthalenyl CH2 3,5-di-Br-2,4-di-OH Ph 50 50
GlyH-302 2-naphthalenyl CH2 3,5-di-Br-4-OH-Ph 50 55
OxaH-303 2-naphthalenyl CO 3,5-di-Br-2,4-di-OH Ph 10 70
OxaH-304 2-naphthalenyl CO 3,5-di-Br-4-OH-Ph 12 78
Group 4 Acetic acid hydrazides (AceH)
Compound R1 R2 Ki (M) % inhibition at 50 M
AceH-401 2-naphthoxy 3,5-di-Br-2,4-di-OH Ph 21 84
AceH-402 2-naphthoxy 3,5-di-Br-4-OH-Ph 17 86
AceH-403 4-Me-Ph 3,5-di-Br-2,4-di-OH Ph 10 54
AceH-404 4-Me-Ph 3,5-di-Br-4-OH-Ph 15 63
Ki is compound concentration giving 50% inhibition of apical membrane Cl current in CFTR-expressing FRT cells. See Fig. 4 for generic structure of compound
groups 1–4.
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102 to NH-CH2 in GlyH-301 and GlyH-302, or to NH-
CO in GlyH-201 and GlyH-202, reduced CFTR inhibi-
tory potency.
Fig. 3 C shows apical Cl current analysis of CFTR in-
hibition in FRT cells for the most active analogue
OxaH-110. Dose–response data for some of the most
potent CFTR inhibitors gave Ki values (in M, SEM,
n  3) of 2.7  0.3 (OxaH-110), 4.3  0.9 (GlyH-101),
4.7  0.9 (GlyH-102), 4.7  0.3 (GlyH-109), and 6.7 
0.9 (GlyH-115).
Patch-clamp Analysis of CFTR Inhibition Mechanism
The mechanism of CFTR block by GlyH-101 was stud-
ied using the whole-cell configuration of the patch-
clamp technique. After maximal activation of CFTR in
stably transfected FRT cells by 5 M forskolin, current–
voltage relationships were measured at GlyH-101 con-
centrations from 0 to 50 M. Representative original
current recordings are shown in Fig. 5 A. In the ab-
sence of inhibitor (left), membrane current increased
linearly with voltage and did not show relaxation phe-
nomena, as expected for pure CFTR Cl currents. Ex-
tracellular perfusion with 10 M GlyH-101 produced a
reduction in current that was strongly dependent on
membrane potential (Fig. 5 A, right). At more positive
membrane potentials, outward positive currents (Cl
movement into the cell) were reduced compared with
Figure 4. General structures of the synthesized compounds. See
Table I for list of substituents and CFTR inhibition activities.
Figure 5. Patch-clamp analysis of
GlyH-101 inhibition mechanism.
(A) Superimposed whole-cell mem-
brane currents evoked by voltages
from 100 to 100 mV (20-mV
steps) in CFTR-expressing FRT cells
after maximal CFTR stimulation by
5 M forskolin. Holding potential
was 100 mV and interpulse dura-
tion was 4 s. Data shown before
(left) and after (right) 10 M GlyH-
101. (B) Current–voltage relation-
ships in the absence of inhibitors
(control, open circles), after addition
of 10 M (filled squares) and 30 M
(open squares) GlyH-101, after
washout of 10 M GlyH-101 (recov-
ery, shaded circles), and after addi-
tion of 5 M CFTRinh-172 (filled
circles). (C) Dose–response for
inhibition of CFTR Cl current by
GlyH-101 at indicated membrane
potentials. Each point is the mean 
SEM of four to five experiments.
Data were fitted to the Hill equa-
tion. Fitted Ki: 1.4  0.4, 3.8  0.2,
5.0  0.3, and 5.6  0.4 M for
voltages of 60, 20, 20, and 60
mV, respectively. Ki at 20 and 60
mV significantly greater than at 20
(P  0.05) and 60 mV (P  0.02).
(D) Effect of reducing extracellular
Cl concentration on apparent
GlyH-101 potency. GlyH-101 dose–
response in high (150 mM) vs. low
(20 mM) extracellular Cl (mean 
SEM, four sets of experiments).
Membrane potential was 20 mV.
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inward currents. Fig. 5 B shows current–voltage rela-
tionships for GlyH-101 concentrations of 0 (control),
10, and 30 M, and after washout of 10 M GlyH-101
(recovery). Data for the thiazolidinone CFTRinh-172 (5
M) is shown for comparison. The current–voltage re-
lationship was linear in the absence of inhibitor, after
GlyH-101 washout, and after inhibition by CFTRinh-172,
whereas GlyH-101 inhibition at submaximal concentra-
tions produced inward rectification. Fig. 5 C summa-
rizes percentage CFTR current block as a function of
GlyH-101 concentration at different membrane volt-
ages. GlyH-101 inhibitory potency was reduced at more
negative voltages, with apparent Ki of 1.4, 3.8, 5.0, and
5.6 M for voltages of 60, 20, 20, and 60 mV, re-
spectively (Hill coefficients, nH  0.5, 0.7, 1.3, 1.8). In
additional studies to investigate whether the GlyH-101
binds to a site in the CFTR pore, Cl flux in the CFTR
pore was altered by reducing extracellular Cl concen-
tration to 20 mM. The potency of GlyH-101 inhibition
of CFTR Cl current was significant reduced at the low
extracellular Cl (Fig. 5 D).
Cell-attached patch-clamp experiments were performed
to investigate the mechanism of GlyH-101 block of
CFTR Cl current at the single-channel level. Fig. 6 A
(representative traces and amplitude histograms) shows
a reduction in apparent CFTR channel activity without
a change in single channel current at GlyH-101 concen-
trations up to 5 M. Mean channel open time was
remarkably reduced, with the appearance of brief
closures during the open bursts whose frequency in-
creased with GlyH-101 concentration (Fig. 6 B).
Physical Properties of Glycine Hydrazides
Interpretation of the voltage-dependent inhibition
mechanism requires knowledge of the GlyH-101 ionic
species that interacts with CFTR. Apical Cl current
studies indicated that the Ki for GlyH-101 inhibition of
CFTR Cl current was independent of pH in the range
6–8 (not depicted), where the compound is highly wa-
ter soluble (0.8–1.3 mM in water, 22	C). The possible ti-
trable groups on GlyH-101 in the pH range 3–10 in-
clude the secondary glycinyl amine and the resorcino-
lic hydroxyls. Spectrophotometric titration of GlyH-101
indicated at least two protonation–deprotonations at
pH between 4 and 9 (Fig. 7 A, top). To assign pKa val-
ues, GlyH-101 analogues that lacked one or more titra-
ble groups were synthesized. Removal of the secondary
amine (AceH-403) had little effect on the titration,
with only a minor left shift of the ascending portion of
the curve, suggesting a pKa of 5.5 for titration of the
first phenolic hydroxyl. Removal of one ortho hydroxyl
(GlyH-102) eliminated the descending portion of the
curve, confirming the pKa of 5.5 for the first para hy-
droxyl and 8.5 for the second ortho hydroxyl. Re-
moval of the aromatic ring containing the resorcinolic
hydroxyls (ethyl N-[2-naphthalenyl] glycinate; Fig. 7 A,
bottom) indicated a pKa 4.7 for the residual second-
ary amine. From these data, the deduced equilibria
among the ionic forms of GlyH-101 is shown in Fig. 7 B.
GlyH-101 exists primarily as a singly charged anion at
pH between 6 and 8.
CFTR Inhibition in Mice In Vivo
Inhibition of CFTR-dependent airway epithelial Cl
current in vivo was demonstrated by nasal PD measure-
ments in mice. Nasal PDs were measured continuously
in response to serial solution exchanges in which amil-
oride was added (to block ENaC Na channels)
followed by Cl replacement by gluconate (to induce
Cl-dependent hyperpolarization), forskolin addition
(to activate CFTR), and GlyH-101 addition (to inhibit
CFTR). The representative PD recording in Fig. 8 A
(left) shows hyperpolarizations (more negative PDs)
Figure 6. Single channel analysis of CFTR inhibition by GlyH-
101. (A) Representative traces (left) and corresponding amplitude
histograms (right) obtained from a cell-attached patch. Pipette
potential (Vp) was 60 mV. CFTR was stimulated with forskolin
(5 M) in the absence and presence of GlyH-101 at indicated
concentrations. Dashed lines show zero current level (channels
closed) with downward deflections indicating channel openings
(Cl ions moving from pipette into the cell). Apparent open
channel probability decreased from 0.48 in the absence of inhibitor
to 0.14 at 5 M GlyH-101. (B) Mean channel open times (mean 
SEM, five sets of experiments) as a function of GlyH-101 concen-
tration from cell-attached patch-clamp experiments (*, P  0.05;
**, P  0.01 vs. control).
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following low Cl and forskolin solutions, representing
CFTR-independent and dependent Cl currents, re-
spectively. Topical application of GlyH-101 in the perfu-
sate rapidly reversed the forskolin-induced hyperpolar-
ization. Averaged results from a series of measurements
are summarized in Fig. 8 A (right). Paired analysis of
PD changes (PD; Fig. 8 B) indicated 4 mV hyperpo-
larization after forskolin with depolarization of similar
magnitude after GlyH-101; for comparison, data are
shown for CFTRinh-172 from a previous study (Salinas
et al., 2004). In a separate series of experiments, nasal
PDs were measured as in A except that all solutions
contained DIDS or GlyH-101. Fig. 8 C shows partial in-
hibition by DIDS of the (CFTR-independent) hyperpo-
larization produced by low Cl (left), and substantial
inhibition by GlyH-101 of the forskolin-induced hyper-
polarization (right). Together these results indicate
rapid inhibition of upper airway CFTR Cl conduc-
tance by topical GlyH-101.
The efficacy of GlyH-101 in inhibiting cAMP/cholera
toxin–induced intestinal fluid secretion was also evalu-
ated. Short-circuit current was measured in different
Figure 8. GlyH-101 inhibits forskolin-
induced hyperpolarization in nasal po-
tential difference in mice. (A, left) Nasal
PD recording showing responses to
amiloride (100 M) and low Cl (4.7
mM) solutions. Where indicated, the low
Cl solutions contained forskolin (10 M)
without or with GlyH-101 (10 M). (A,
right) Averaged PD values (mean  SEM,
n  5). (B) Paired analysis of experiments
as in A showing PD changes (PD) after
forskolin (10 M), CFTRinh-172 (20 M),
and GlyH-101 (10 M). (C) A series of
experiments was done in which all solu-
tions contained DIDS (100 M) or GlyH-
101 (10 M). PD (mean  SEM) for
low Cl and forskolin-induced hyperpo-
larizations. *, P  0.005 for reduced PD
compared with control. CFTRinh-172 data
taken from Salinas et al. (2004).
Figure 7. Determination of
pH-dependent ionic equilibria of
GlyH-101 by spectrophotometric
titration of GlyH-101 analogues.
(A) Chemical structures (left)
and corresponding pH-depen-
dent absorbance changes (right)
of compounds (10 M) in NaCl
(100 mM) containing MES,
HEPES, boric acid, and citric
acid (each 10 mM) titrated to in-
dicated pH using HCl/NaOH.
Absorbance changes measured
at wavelengths of 346, 348, 346,
and 236 nm (top to bottom).
(B) Deduced ionic equilibria of
GlyH-101 showing pKa values.
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cell types and in intact mouse ileum under nonperme-
abilized conditions and in the absence of a Cl gradi-
ent. In each case, CFTR was activated by CPT-cAMP af-
ter ENaC inhibition by amiloride. Fig. 9 shows similar
Ki  2–5 M for inhibition of cAMP-stimulated short-
circuit current by GlyH-101 in T84 cells (A), primary
human bronchial cell cultures (B), and intact mouse il-
eum (C). Inhibition was 100% at higher GlyH-101
concentrations. Cholera toxin–induced intestinal fluid
secretion was measured in an in vivo closed-loop model
in which loops for each mouse were injected with saline
(control), cholera toxin (1 g), or cholera toxin (1 g) 
GlyH-101 (2.5 g). GlyH-101 was added to the lumen
(rather than systemically) based on initial studies show-
ing poor intestinal absorption and little effect of systemi-
cally administered compound. Referenced to the saline
control, the cholera toxin–induced increase in fluid se-
cretion over 4 h, quantified from loop weight-to-length
ratio, was 80% reduced by GlyH-101 (Fig. 9 D). To rule
out the possibility that GlyH-101 inhibited intestinal
fluid secretion by blocking the binding of cholera toxin
to its cell receptor, T84 cell fluorescence was measured
after 1 h incubation with FITC-labeled cholera toxin B
subunit (50 g/ml) at 37	C. GlyH-101 at 50 M did not
inhibit cholera toxin binding/uptake (not depicted).
D I S C U S S I O N
The glycine hydrazides were discovered using an assay
designed to identify rapidly acting inhibitors of CFTR
that interact with the CFTR pore or a critical part of the
CFTR molecule involved in anion conductance. The ki-
netic and electrophysiological data suggest that glycine
hydrazides block CFTR Cl conductance by occluding
the CFTR anion pore at or near the external mem-
brane surface. Unlike all other CFTR inhibitors, in-
cluding the thiazolidinone CFTRinh-172, CFTR block by
the glycine hydrazide GlyH-101 produced inwardly rec-
tifying CFTR Cl currents. Compared with CFTRinh-
172, GlyH-101 is 50-fold more water soluble and is
rapidly acting/reversible when added to or removed
from the extracellular solution, consistent with its ac-
tion at the external-facing surface of CFTR. Structure–
activity analysis of a series of targeted glycine hy-
drazide analogues defined the structural determinants
for CFTR inhibition and provided analogues with greater
CFTR inhibitory potency, the best being OxaH-110
with Ki 2 M. Although the most potent thiazolidi-
none CFTRinh-172 has Ki of 0.2–0.3 M in permeabi-
lized cell preparations, its Ki is 2–5 M in many intact
epithelial cells because of the interior negative mem-
brane potential that reduces its concentration in cyto-
plasm (Thiagarajah et al., 2004a). Thus, the glycine hy-
drazides are as or more potent than the thiazolidi-
nones, and like the thiazolidinones, they block CFTR
in nasal and intestinal epithelia in vivo.
Patch-clamp studies indicated that CFTR inhibition
by GlyH-101 is sensitive to membrane potential. At sub-
maximal concentrations of GlyH-101, there was marked
inward rectification in the CFTR current–voltage rela-
tionship, indicating that Cl flux from the extracellular
to the intracellular side of the membrane is more
strongly blocked than that in the opposite direction.
The apparent Ki increased approximately fourfold as
applied potential was varied from 60 to 60 mV.
Since GlyH-101 is negatively charged at pH 6–8, the
simplest interpretation of these data is that GlyH-101
inhibition involves direct interaction with the channel
Figure 9. GlyH-101 inhibits cholera
toxin/cAMP-dependent intestinal
fluid secretion. (A–C) Inhibition of
short-circuit current by GlyH-101 after
CFTR stimulation in T84 cells (A),
human airway cells (B), and mouse
ileum (C). Following constant base-
line current, amiloride (10 M, apical
solution) and CPT-cAMP (0.1 mM,
both solutions) were added, followed
by indicated concentrations of GlyH-
101 (both solutions). Indomethacin
(10 M) was present in all solutions in
ileum studies. Experiments represen-
tative of three to five measurements.
(D) Closed intestinal loop model of
cholera toxin–induced fluid secretion.
Intestinal luminal fluid, shown as loop
weight/length (g/cm, SEM, six mice),
measured at 4 h after injection of
saline (control), cholera toxin (1 g),
or cholera toxin given together with
GlyH-101 (2.5 g). *, P  0.01.
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pore at the extracellular side of the membrane. Ac-
cordingly, negative membrane potentials reduce the in-
hibitory efficacy of the negatively charged GlyH-101 by
electrostatic repulsion, which drives the compound
away from the pore. In contrast, the open channel
blocker glibenclamide, which is thought to act from
the intracellular side of the CFTR pore (Sheppard and
Robinson, 1997), produces outward rectification of
CFTR current–voltage relationship (Zhou et al., 2002).
The reduced GlyH-101 potency at low extracellular Cl
concentration provided further evidence that GlyH-101
binds to a site at the external CFTR pore.
Analysis of GlyH-101 dose–response data also re-
vealed an increase in apparent Hill coefficient at more
negative membrane potentials, suggesting the possibil-
ity of more than one inhibitor binding site within the
pore and/or cooperative interaction between inhibitor
molecules, as reported previously for other ion chan-
nels (Pottosin et al., 1999; Brock et al., 2001). In sup-
port of the hypothesis that GlyH-101 is an open chan-
nel blocker, cell-attached patch-clamp experiments re-
vealed fast closures within bursts of channel openings.
The frequency of fast closures increased with GlyH-101
concentration, producing a reduction in mean channel
open time as found for glibenclamide (Sheppard and
Robinson, 1997). The appearance of closure events on
the millisecond time scale classifies GlyH-101 as an “in-
termediate”-type channel blocker, similar to glibencla-
mide; in contrast, “fast” blockers reduce apparent sin-
gle channel conductance, and “slow” blockers cause
closures of many seconds duration (Hille, 1992). In
whole-cell patch-clamp and apical Cl current experi-
ments, CFTR Cl conductance was nearly completely
inhibited at high concentrations (30 M) of GlyH-
101. Together these results suggest that the GlyH-101
inhibition mechanism involves direct CFTR pore occlu-
sion at a site at or near the extracellular-facing pore
surface.
Synthesis and characterization of a series of glycine
hydrazide analogues indicated the important structural
determinants for CFTR inhibition. Synthesis work was
directed to alter polarity, planarity, and hydrophilic/hy-
drophobic properties of the GlyH-101, systematically
modifying different portions of the molecule as dia-
grammed in Fig. 3 A. Slight changes in planarity by re-
placing the glycinyl methylene group (R2) with car-
bonyl group improved inhibition activity, whereas re-
duction of Schiff base group (NC) reduced activity.
An extensive set of modifications of the benzaldehyde
moiety (R3) indicated the requirement of two bromines
separated by one para-hydroxyl group. Replacement of
the 2-naphthalenyl group by (hetero)aromatic groups
reduced inhibition activity. Many GlyH-101 analogues
having substitutions that reduced overall polarity were
inactive, suggesting that the presence of a hydrophobic
group at one end at R1 and an anion group at R3 are
key requirements for CFTR inhibition activity. Molecu-
lar docking computations should be informative when
structural information about the CFTR pore becomes
available.
In summary, the glycine hydrazides represent a new
class of potent CFTR inhibitors with a novel external
pore-occluding mechanism producing inward rectifica-
tion and a reduction in mean channel open time. The
large series of structural analogues with varying activi-
ties should permit the synthesis of engineered ana-
logues with specified ADME (administration, distri-
bution, metabolism, excretion) and other properties,
such as membrane impermeability. The antidiarrheal
efficacy of GlyH-101 when added in the intestinal lu-
men rather than systemically is particularly interesting,
and suggests the possibility of developing a nonabsorb-
able drug for reducing intestinal fluid loss in secretory
diarrheas produced by Vibrio cholera and Escherichia coli.
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